Partner News | Published: Monday, May 8, 2023
egnite, Inc., a leading digital health company and a MedAxiom partner, announced a strategic partnership with Ancora Heart, Inc., a medical device company developing a novel transcatheter device-based therapy addressing heart failure (HF) to accelerate enrollment for Ancora Heart’s CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System. The partnership brings together the cutting-edge technology and expertise of both organizations with the goal of delivering innovative therapies to patients faster. The Christ Health Network in Cincinnati, OH is the first site in Ancora Heart’s CORCINCH-HF trial to utilize egnite’s Trial Accelerator artificial intelligence (AI) technology to help identify eligible patients.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
